Acoustic NeuromaSymptoms, Doctors, Treatments, Advances & More
Acoustic Neuroma Overview
Learn About Acoustic Neuroma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Corewell Health William Beaumont University Hospital Neurology - 3555 W 13 Mile
Jeffrey Jacob is a Neurosurgery provider practicing medicine in Royal Oak, Michigan. Dr. Jacob is rated as an Elite provider by MediFind in the treatment of Acoustic Neuroma. He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Acoustic Neuroma, Schwannoma, Subependymoma, Gamma Knife Radiosurgery, and Awake Craniotomy. Dr. Jacob is board certified in American Board Of Neurological Surgery. Dr. Jacob is currently accepting new patients.
Johns Hopkins Outpatient Center
Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care. Dr. Blakeley is rated as an Elite provider by MediFind in the treatment of Acoustic Neuroma. She is also highly rated in 27 other conditions, according to our data. Her clinical expertise encompasses Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy. Dr. Blakeley is board certified in American Board Of Psychiatry And Neurology.
Michigan Ear Institute
Seilesh Babu is an Otolaryngologist practicing medicine in Farmington Hills, Michigan. He has been practicing medicine for over 29 years. Dr. Babu is rated as an Elite provider by MediFind in the treatment of Acoustic Neuroma. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Acoustic Neuroma, Schwannoma, Otosclerosis, Stapedectomy, and Mastoidectomy. Dr. Babu is board certified in American Board Of Otolaryngology - Head And Neck Surgery and American Board Of Otolaryngology - Head And Neck Surgery. Dr. Babu is currently accepting new patients.
Summary: Objective With this prospective natural experiment trial on neurofibromatosis type 2 (NF2) study, we hope to understand the factors leading to tumor progression and neurological disease burden in NF2. Study Population A total of 269 participants, ages 8-75, with a clinical or genetic diagnosis of NF2 will participate in this study. Design Study participants will be evaluated with a thorough physic...
Summary: This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product performance.


